XML 111 R62.htm IDEA: XBRL DOCUMENT v3.21.1

Business Combinations - Additional Information (Details) shares in Millions, $ in Millions					12 Months Ended
	Oct. 31, 2020 EUR (€)	May 06, 2020 EUR (€) NeoantigenTargetedTherapy shares	Jan. 06, 2020 EUR (€)	Jan. 01, 2020 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)	Dec. 31, 2018 EUR (€)	May 06, 2020 USD ($) shares
Disclosure Of Business Combinations [Line Items]
Operating loss					€ (82,417,000)	€ (181,518,000)	€ (53,854,000)
Revenues					482,325,000	108,589,000	€ 127,575,000
Share capital					246,310,000	232,304,000
Lipocalyx GmbH
Disclosure Of Business Combinations [Line Items]
Name of acquiree			Lipocalyx GmbH
Cash consideration			€ 6,500,000			6,516,000
Date of acquisition			Jan. 06, 2020
Estimated contingent consideration			€ 600,000			572,000
Operating loss			(1,700,000)
Revenues			200,000
Transaction costs			€ 17,000
Lipocalyx GmbH | Phase 1 Clinical Trial
Disclosure Of Business Combinations [Line Items]
Contingent cash consideration						1,000,000
Lipocalyx GmbH | Phase 2 Clinical Trial
Disclosure Of Business Combinations [Line Items]
Contingent cash consideration						€ 1,000,000
BioNTech US Inc.
Disclosure Of Business Combinations [Line Items]
Cash consideration		€ 342,000
Operating loss				€ (59,800,000)	(28,500,000)
Revenues					0
Transaction costs		1,100,000
Aggregate value of merger consideration		€ 89,900,000						$ 97.1
American depositary shares | shares		1,935,488						1,935,488
Deferred tax liabilities recognized		€ 8,000,000
Share capital		€ 1,300,000
BioNTech US Inc. | In-process R&D
Disclosure Of Business Combinations [Line Items]
Intangible assets, number of neoantigen targeted therapies under development | NeoantigenTargetedTherapy		2
BioNTech Manufacturing Marburg GmbH
Disclosure Of Business Combinations [Line Items]
Name of acquiree	Novartis Manufacturing GmbH
Cash consideration	€ 77,853,000
Date of acquisition	Oct. 31, 2020
Operating loss					(6,700,000)
Revenues					€ 0
Transaction costs	€ 1,400,000
Bargain purchase	€ 7,002,000

X

- Definition

American depositary shares.

+ References

No definition available.

+ Details

Name:	bntx_AmericanDepositaryShares
Namespace Prefix:	bntx_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Bargain purchase gain on acquisition.

+ References

No definition available.

+ Details

Name:	bntx_BargainPurchaseGainOnAcquisition
Namespace Prefix:	bntx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Business combination maximum potential contingent cash consideration.

+ References

No definition available.

+ Details

Name:	bntx_BusinessCombinationContingentCashConsideration
Namespace Prefix:	bntx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Consideration transferred.

+ References

No definition available.

+ Details

Name:	bntx_ConsiderationTransferred
Namespace Prefix:	bntx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Intangible assets, number of neoantigen targeted therapies under development.

+ References

No definition available.

+ Details

Name:	bntx_IntangibleAssetsNumberOfNeoantigenTargetedTherapiesUnderDevelopment
Namespace Prefix:	bntx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of acquisition-related costs recognised as an expense for transactions that are recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2020-01-01
-Paragraph B64
-Subparagraph m
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2020-01-01
-Paragraph B64
-Subparagraph f
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_CashTransferred
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2020-01-01
-Paragraph B64
-Subparagraph g
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B64_g_i&doctype=Appendix&subtype=B
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The date on which the acquirer obtains control of the acquiree in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2020-01-01
-Paragraph B64
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B64_b&doctype=Appendix&subtype=B
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_DateOfAcquisition2013
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IFRS
-Number 3
-IssueDate 2020-01-01
-Paragraph B64
-Subparagraph i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfBusinessCombinationsLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The nominal value of capital issued.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 78
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78_e&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_IssuedCapital
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The name of the business or businesses that the acquirer obtains control of in a business combination. [Refer: Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2020-01-01
-Paragraph B64
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B64_a&doctype=Appendix&subtype=B
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_NameOfAcquiree
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 32
-IssueDate 2020-01-01
-Paragraph IE33
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2020-en-r&anchor=para_IE33&doctype=Illustrative%20Examples
-URIDate 2020-01-01

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 85
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_85&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_ProfitLossFromOperatingActivities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2020-01-01
-Paragraph 113
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_113_a&doctype=Standard
-URIDate 2020-01-01

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2020-01-01
-Paragraph 114
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_114&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=bntx_LipocalyxGmbHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ItemsOfContingentLiabilitiesAxis=bntx_PhaseOneClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ItemsOfContingentLiabilitiesAxis=bntx_PhaseTwoClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=bntx_BioNTechUSIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=bntx_BioNTechManufacturingMarburgGmbHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: